Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants

WR Strohl, Z Ku, Z An, SF Carroll, BA Keyt, LM Strohl - BioDrugs, 2022 - Springer
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lectin receptor DC-SIGN

LEH van der Donk, M Bermejo-Jambrina… - PLoS …, 2023 - journals.plos.org
SARS-CoV-2 causes COVID-19, an infectious disease with symptoms ranging from a mild
cold to severe pneumonia, inflammation, and even death. Although strong inflammatory …

Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages

L Xu, Y Chen, L Liu, X Hu, C He, Y Zhou, X Ding… - Plos …, 2024 - journals.plos.org
Tumor-associated macrophages (TAM) subtypes have been shown to impact cancer
prognosis and resistance to immunotherapy. However, there is still a lack of systematic …

SARS CoV-2 spike protein variants exploit DC-SIGN/DC-SIGNR receptor for evolution and severity: an in-silico insight

J Gupta, MZ Malik, M Chaturvedi, M Mishra, SK Mishra… - VirusDisease, 2023 - Springer
Abstract The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is related
with the COVID-19 pandemic. Recent spike protein variations have had an effect on the …

Cheminformatics Screening of Phytochemicals Targeting Diverse Potential Receptors to Elicit Antiviral Properties

R Kumar, G Gupta, A Mohan, M Gupta - Coronaviruses, 2024 - benthamdirect.com
Objective: Recently, the COVID-19 (coronavirus disease) pandemic caused by SARSCoV-2
(severe acute respiratory syndrome coronavirus) gave rise to a public health emergency …